Not likely. Premature ending of clinical trials is associated with life saving drugs. The ending allows the control (the group that did not get the drug) to participate. Afrezza is not a life saving drug.
A very high possibility. If you noticed in that Article that DNDN and MNKD were mentioned. This stock haven't yet realized the potential for an earlier end of trial. Watch what happens when it touches $5.00 and any mention of early submission to FDA. Just do not blink when it happens, it is why you own MNKD now at these levels.